Alexion Pharmaceuticals

At the heart of what we do is a culture of commitment and innovation. Alexion Pharmaceuticals, Inc., now part of AstraZeneca, is a global biopharmaceutical company that focuses exclusively on developing and delivering life-changing therapies for patients living with devastating rare diseases. Our mission revolves around transforming the lives of individuals affected by rare conditions, which often results in serious health challenges and significant obstacles to diagnosis and treatment. By centering our efforts around the patient, we ensure that our innovations help heal not just the individual but also the communities they are part of.

Our journey began in 1992, and since then, we have made significant strides in advancing our drug development pipelines. With six approved medicines addressing conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), we continuously seek to innovate in complement biology, where our pioneering work originally took root. Every day, we take bold steps to improve health equity for those living with rare diseases while listening to the needs of the patient community. Our dedicated team works tirelessly to foster an inclusive environment that values diverse perspectives and drives innovation. In doing so, we inspire hope and create a better tomorrow for patients and families around the world.